Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Abstract: The disclosure provides methods for treating, preventing, and reducing the incidence of opioid-induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.

Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Abstract: The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.

Abstract: The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.

Abstract: The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome.

Abstract: The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3I s C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by